Savioke (Relay Robotics): Company Profile

Relay Robotics Builds Healthcare Moat Around Indoor Delivery, But Capital Constraints Loom Large

Relay Robotics — the company formed from the 2022 acquisition of pioneer Savioke — has accumulated 1.5 million autonomous indoor deliveries across hospitals and hotels, establishing one of the more credible operational track records in the service robotics segment. The company's pivot toward hospital-grade chain-of-custody workflows, including chemotherapy delivery at MedStar Georgetown University Hospital, represents a defensible niche. Whether a $10M Series A — the last publicly disclosed funding round — is sufficient to hold that position against well-capitalized Asian OEMs is the central question facing the business.

Signal Activity — Savioke (Relay Robotics)

Deal History — Savioke (Relay Robotics)

Competitive Positioning — Savioke (Relay Robotics)

Business Overview

Relay Robotics was constituted in May 2022 when Relay Robotics Inc. acquired Savioke, consolidating the Relay product line, IP portfolio, customer agreements, and core team. Michael O'Donnell was appointed Chairman and CEO; Steve Cousins, a Savioke co-founder, continued as CTO. The $10M Series A, led by MK Capital, closed concurrently with the acquisition.

The company operates across two primary verticals — hospitality and healthcare — with the strategic center of gravity visibly shifting toward healthcare. Hospitality deployments include Dream Hollywood (Los Angeles), Westin Buffalo (New York), AC Hotel Southpointe (Pennsylvania), and all eight properties of Seaview Investors. Healthcare deployments include IU Health (2024) and MedStar Georgetown University Hospital (2025), where robots are integrated into chemotherapy preparation and delivery workflows.

Geographic presence is concentrated in the United States, with early-stage expansion into Canada announced in April 2024. No evidence of meaningful international scale exists at this time. (MODERATE CONFIDENCE)

Technology

The Relay platform is a wheeled indoor UGV designed for last-yard delivery in multi-floor, human-occupied environments. Its defining technical capability is autonomous elevator operation — robots call, enter, select floors, and exit elevators after configuration during installation — a capability that few competitors have demonstrated at comparable deployment scale.

Capability	Relay Platform	Notes
Elevator autonomy	Yes	Configured per-site during installation
Payload	10-gallon bin	Passive thermal insulation, ±1°F ambient
Delivery success rate	99.8%	Company-reported; no independent validation
Lifetime deliveries	1.5M+	As of April 2024
Monthly throughput	25,000+	Company-reported
Annual distance	10,000+ miles	Fleet aggregate
IP portfolio	10 granted U.S. patents	20 total filings as of 2022

The Relay+ variant, launched December 2021, introduced configurable payload options (single lockable bin; four-drawer model) and a Rapid Install capability designed to compress deployment timelines to days rather than months. Early marketing claimed elevator operation "without expensive elevator integration" — language that has since been qualified to reflect site-specific configuration requirements, a discrepancy worth scrutinizing in procurement conversations.

The hospital-specific product iteration announced in June 2023 emphasizes chain-of-custody security: lockable compartments, authentication workflows, and audit trails with full delivery history. These features align with pharmacy compliance requirements and create switching costs that commodity hospitality robots cannot easily replicate.

Market Position

Relay Robotics occupies a narrow but defensible position in hospital-grade indoor autonomous delivery. The competitive landscape is bifurcated: well-funded Asian OEMs (Pudu Robotics, Keenon) compete aggressively on price in hospitality, while the healthcare segment remains less penetrated and more technically demanding.

The company's 10+ granted U.S. patents, 1.5M-delivery operational dataset, and clinical reference sites (MedStar Georgetown, IU Health) constitute a meaningful barrier in healthcare procurement, where reference deployments and compliance alignment carry disproportionate weight. The Seaview Investors multi-property commitment demonstrates land-and-expand dynamics in hospitality, though margin pressure from lower-cost competitors in that vertical is a structural concern.

The core risk is capital asymmetry. Pudu Robotics has raised hundreds of millions of dollars; Relay Robotics' last disclosed raise was $10M in 2022. No subsequent public funding round has been announced. (HIGH CONFIDENCE on funding gap; LOW CONFIDENCE on current burn rate or runway)

Outlook

Three catalysts could materially alter Relay Robotics' trajectory: a new funding round that enables geographic and product expansion; a multi-system enterprise deal with a large hospital integrated delivery network; or deeper clinical integration with pharmacy and EHR systems that would substantially raise switching costs and expand addressable workflow.

The acqui-hire risk is real. The company's IP portfolio, clinical reference base, and technical team represent attractive assets for a larger player — a hospital systems integrator, a medical device company, or a well-capitalized robotics platform — seeking to enter or accelerate in autonomous hospital logistics without building from scratch.

Relay Robotics is a credible operator in a difficult segment. The technology is field-proven, the healthcare pivot is strategically sound, and the IP position is meaningful for a company of this scale. Execution against better-funded competition, without a disclosed path to additional capital, remains the defining constraint.

---

Coverage confidence: MODERATE. Key financials — revenue, unit economics, fleet size — are undisclosed. Operational metrics are company-reported without independent third-party validation.